Extinction Based Treatment for Nicotine Dependence
Extinction01
Brain Substrates of Extinction Based Treatment for Nicotine Dependence
1 other identifier
interventional
257
1 country
1
Brief Summary
The purpose of this study is to test two quit smoking therapies and to study brain function while each therapy is being used. You will be randomly assigned (like flipping a coin) to one of the two groups. The first therapy is Extinction-Based therapy (EBT). If you are in this group, you will switch to smoking denicotinized cigarettes while wearing a 21 mg/d nicotine patch for one month prior to your quit date. The second therapy is a standard Nicotine Replacement therapy (NRT). If you are in this group, you will smoke your usual brand of cigarettes up to the quit date. Following the quit date, both groups will undergo standard nicotine replacement therapy (21 mg/d for 6 weeks; 14 mg/d for 2 weeks, 7 mg/d for 2 weeks). In addition to the above, we will recruit a sample of former smokers who are now regular users of e-cigarettes. This group \[ECIG\] will undergo the same screening and baseline assessments as the EBT and NRT groups up to the completion of fMRI1.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Jan 2009
Longer than P75 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2009
CompletedFirst Submitted
Initial submission to the registry
January 27, 2009
CompletedFirst Posted
Study publicly available on registry
January 28, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2014
CompletedApril 20, 2015
April 1, 2015
5.9 years
January 27, 2009
April 17, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To test two quit smoking therapies and to study brain function while each therapy is being used.
14 weeks
Study Arms (2)
1
ACTIVE COMPARATORExtinction Based Group (EBT): switch to smoking denicotinized cigarettes while wearing a 21mg/day nicotine patch for one month prior to their quit date.
2
NO INTERVENTIONNicotine Replacement Group (NRT): smoke their usual brand of cigarettes up to the quit date.
Interventions
Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
Eligibility Criteria
You may qualify if:
- generally healthy,
- between the ages of 18 and 55,
- smoking of at least 10 cigarettes/day of a brand delivering \>0.5mg nicotine according to the standard Federal Trade Commission (FTC) method,
- an afternoon expired CO concentration of at least 10 ppm (to confirm inhalation),
- an interest in quitting smoking
- right-handed
- generally healthy,
- between the ages of 18 and 55,
- prior history of smoking of at least 10 conventional cigarettes/day for at least two years of a brand delivering \>0.5mg nicotine according to the standard Federal Trade Commission (FTC) method,
- no smoking of conventional cigarettes in the last 6 months;
- daily use of a nicotine-containing e-cigarette for at least 3 months;
- taking of at least 100 puffs per day from a nicotine-containing e-cigarette;
- an afternoon expired CO concentration \<5 ppm (to confirm they are not combustible cigarette users);
- nicotine test strip reading \>3
- right-handed
You may not qualify if:
- inability to attend all required experimental sessions,
- significant health problems (e.g., chronic hypertension (BP\>150/90 sitting after 10 minutes), emphysema, seizure disorder, history of significant heart problems),
- use of psychoactive medications,
- use of smokeless tobacco,
- liver or kidney disorder (except kidney stones, gallstones)
- lung disorder (including but not limited to COPD, emphysema, and asthma)
- report of coronary heart disease; heart attack; cardiac rhythm disorder (irregular heart rhythm; chest pains; cardiac disorder (including but not limited to valvular heart disease, heart murmur, heart failure)
- current alcohol or drug abuse,
- use of illegal drugs as measured by urine drug screen,
- current use of nicotine replacement therapy or other smoking cessation treatment,
- presence of conditions that would make MRI unsafe (e.g., pacemaker, metal objects in the body, IUD, orthopedic pins or screws, etc.), or
- presence of conditions contraindicated for nicotine replacement therapy (e.g., skin allergies or disorders).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Duke Universitylead
Study Sites (1)
Duke Medical Center
Durham, North Carolina, 27705, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Francis J McClernon, Ph.D
Duke University
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 27, 2009
First Posted
January 28, 2009
Study Start
January 1, 2009
Primary Completion
December 1, 2014
Study Completion
December 1, 2014
Last Updated
April 20, 2015
Record last verified: 2015-04